RBC Capital analyst Ben Hendrix raised the firm’s price target on Bright Health to $16 from $13 and keeps a Sector Perform rating on the shares. The company’s continuing operations saw “solid results” while its liquidity concerns are easing with the pending sale of California Medicare Advantage business, the analyst tells investors in a research note. Bright Health has also made substantial progress in managing the liability in its discontinued operations, reaching 95% claims completion at the end of the quarter, the firm added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BHG:
- Largest borrow rate increases among liquid names
- Bright Health lowers FY23 revenue view to $1.15B-$1.2B from $2.9B-$3.1B
- Bright Health reports Q2 EPS ($15.70), consensus ($5.44)
- Bright Health rises 8.0%
- Bright Health falls -5.9%
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue